10:16 AM EST - StageZero Life Sciences : Today announced its first quarter financial results for the three months ended March 31, 2023. For the quarter, the Company generated revenue of $0.779 million, compared to revenue of $0.676 million for the three months ended December 31, 2022. Net loss was $1.8 million, or $0.02 loss per fully diluted common share in Q1 2023 as compared to a $9.5 million net loss, or $0.09 loss per fully diluted common share in Q4 2022. StageZero Life Sciences
shares T.SZLS are trading down $0.01 at $0.06.
